Aldh inhibitor restores auditory function in a mouse model of human deafness
Guang-Jie Zhu,Sihao Gong,Deng-Bin Ma,Tao Tao,Wei-Qi He,Linqing Zhang,Fang Wang,Xiao-Yun Qian,Han Zhou,Chi Fan,Pei Wang,Xin Chen,Wei Zhao,Jie Sun,Huaqun Chen,Ye Wang,Xiang Gao,Jian Zuo,Min-Sheng Zhu,Xia Gao,Guoqiang Wan
DOI: https://doi.org/10.1371/journal.pgen.1009040
IF: 4.5
2020-09-24
PLoS Genetics
Abstract:Genetic hearing loss is a common health problem with no effective therapy currently available. DFNA15, caused by mutations of the transcription factor POU4F3, is one of the most common forms of autosomal dominant non-syndromic deafness. In this study, we established a novel mouse model of the human DFNA15 deafness, with a <em>Pou4f3</em> gene mutation (<em>Pou4f3Δ</em>) identical to that found in a familial case of DFNA15. The <em>Pou4f3(Δ/+)</em> mice suffered progressive deafness in a similar manner to the DFNA15 patients. Hair cells in the <em>Pou4f3(Δ/+)</em> cochlea displayed significant stereociliary and mitochondrial pathologies, with apparent loss of outer hair cells. Progression of hearing and outer hair cell loss of the <em>Pou4f3(Δ/+)</em> mice was significantly modified by other genetic and environmental factors. Using <em>Pou4f3(-/+)</em> heterozygous knockout mice, we also showed that DFNA15 is likely caused by haploinsufficiency of the <em>Pou4f3</em> gene. Importantly, inhibition of retinoic acid signaling by the aldehyde dehydrogenase (Aldh) and retinoic acid receptor inhibitors promoted Pou4f3 expression in the cochlear tissue and suppressed the progression of hearing loss in the mutant mice. These data demonstrate <em>Pou4f3</em> haploinsufficiency as the main underlying cause of human DFNA15 deafness and highlight the therapeutic potential of Aldh inhibitors for treatment of progressive hearing loss.More than 50% of deafness cases are due to genetic defects with no treatment available. DFNA15, caused by mutations of the transcription factor <em>POU4F3</em>, is one of the most common types of autosomal dominant non-syndromic deafness. Here, we established a novel mouse model with the exact <em>Pou4f3</em> mutation identified in human patients. The mutant mouse display similar auditory pathophysiology as human patients and exhibit multiple hair cell abnormalities. The onset and severity of hearing loss in the mouse model is highly modifiable to environmental factors, such as aging, noise exposure or genetic backgrounds. Using a new knockout mouse model, we found Pou4f3 haploinsufficiency as the underlying mechanism of human DFNA15. Importantly, we identified Aldh inhibitor as a potent small molecule for upregulation of Pou4f3 and treatment of hearing loss in the mutant mouse. The identification of Aldh inhibitor for treatment of DFNA15 deafness represents a major advance in the unmet medical need for this common form of progressive hearing loss.
genetics & heredity